We are live on
!
Find out more
BRA
Bender Robert & Associates Portfolio holdings
AUM
$481M
1-Year Est. Return
35.73%
This Fund
S&P 500
This Quarter
Est. Return
+1.38%
1 Year Est. Return
+35.73%
3 Year Est. Return
+116.09%
5 Year Est. Return
+167.64%
10 Year Est. Return
+1,066.43%
AUM
$349M
AUM Growth
-$2.6M
(-0.74%)
Cap. Flow
-$4.7M
Cap. Flow
% of AUM
-1.35%
Top 10 Holdings %
Top 10 Hldgs %
72.52%
Holding
51
New
4
Increased
8
Reduced
32
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$3.41M |
| 2 |
AstraZeneca
AZN
|
+$2.71M |
| 3 |
Idexx Laboratories
IDXX
|
+$339K |
| 4 |
Advanced Micro Devices
AMD
|
+$290K |
| 5 |
ServiceNow
NOW
|
+$245K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$4.11M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$3.67M |
| 3 |
Apple
AAPL
|
+$770K |
| 4 |
Intuitive Surgical
ISRG
|
+$393K |
| 5 |
BAND
Bandwidth Inc
BAND
|
+$371K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.37% |
| 2 | Consumer Discretionary | 29.92% |
| 3 | Healthcare | 21.28% |
| 4 | Communication Services | 12.55% |
| 5 | Industrials | 1.16% |
Similar funds
MA
WAS
SA
NC
HWMG
MAV
OMIC
SCA
Bender Robert & Associates's Q3 2021 Portfolio in Review
As of Q3 2021, Bender Robert & Associates held 51 positions worth $349M, down 0.74% from $352M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Bender Robert & Associates's Q3 2021 filing shows 4 new, 8 increased, 32 reduced and 2 closed positions. Its largest new stake was AstraZeneca: 23,290 shares worth $2.8M. The largest sale was Alexion Pharmaceuticals, an estimated $4.11M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 34% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Bender Robert & Associates's largest Q3 2021 buy was AstraZeneca: 23,290 shares worth $2.8M.
- Bender Robert & Associates added most to Alphabet (Google) Class C in Q3 2021, an estimated $3.41M increase.
- Bender Robert & Associates's biggest Q3 2021 reduction was Alphabet (Google) Class A, cutting an estimated $3.67M.
- Bender Robert & Associates fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $4.11M.
- Bender Robert & Associates's ten largest holdings make up 73% of its $349M portfolio in Q3 2021.
- Bender Robert & Associates opened 4 new positions and closed 2 in Q3 2021.
- Bender Robert & Associates's portfolio value fell 0.74% quarter-over-quarter to $349M.
Based on Bender Robert & Associates's 13F filing for Q3 2021, filed 3 Nov 2021.